EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates

Petros Ioannou iD, Athanasios Katsigiannis, Ioanna Papakitsou, Ioannis Kopidakis, Eirini Makraki, Dimitris Milonas, Theodosios D Filippatos iD, George Sourvinos iD, Marina Papadogiannaki, Evaggelia Lydaki, Georgios Chamilos, Diamantis P Kofteridis iD

Viruses · 2023

DOI: 10.3390/v15030756 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Petros Ioannou und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Crete, 71003 Heraklion, Greece. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients receiving treatment with B-cell-depleting monoclonal antibodies, such as anti-CD20 monoclonal antibodies, such as rituximab and obinutuzumab, either for hematological disease or another diagnosis, such as a rheumatological disease, are at an increased risk for medical complications and mortality from COVID-19. Since inconsistencies persist regarding the use of convalescent plasma (CP), especially in the vulnerable patient population that has received previous treatment with B-cell-depleting monoclonal antibodies, further studies should be performed in thisdirection. The aim of the present study was to describe the characteristics of patients with previous use of B-cell-depleting monoclonal antibodies and describe the potential beneficial effects of CP use in terms of mortality, ICU admission and disease relapse. In this retrospective cohort study, 39 patients with previous use of B-cell-depleting monoclonal antibodies hospitalized in the COVID-19 department of a tertiary hospital in Greece were recorded and evaluated. The mean age was 66.3 years and 51.3% were male. Regarding treatment for COVID-19, remdesivir was used in 89.7%, corticosteroids in 94.9% and CP in 53.8%. In-hospital mortality was 15.4%. Patients who died were more likely to need ICU admission and also had a trend towards a longer hospital stay, even though the last did not reach statistical significance. Patients treated with CP had a lower re-admission rate for COVID-19 after discharge. Further studies should be performed to identify the role of CP in patients with treatment with B-cell-depleting monoclonal antibodies suffering from COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansMaleAgedFemaleSARS-CoV-2Retrospective StudiesImmunization, PassiveCOVID-19 SerotherapyAntibodies, Monoclonal

Stichwörter der Autor:innen

COVID-19ObinutuzumabSARS-CoV-2anti-CD20convalescent plasmalymphomarituximab

Substanzen

Antibodies, Monoclonal

Autor:innen und Institutionen

  • School of Medicine, University of Crete, 71003 Heraklion, Greece.
  • COVID-19 Department, University Hospital of Heraklion, 71110 Heraklion, Greece.
  • Laboratory of Clinical Virology, School of Medicine, University of Crete, 71003 Heraklion, Greece.
  • Department of Blood Transfusion, University Hospital of Heraklion, 71110 Heraklion, Greece.
  • Microbiology Department, University Hospital of Heraklion, 71110 Heraklion, Greece.

ORCID-Profile: Petros Ioannou, Theodosios D Filippatos, George Sourvinos, Diamantis P Kofteridis

Zitieren

APA

Ioannou, P., Katsigiannis, A., Papakitsou, I., Kopidakis, I., Makraki, E., Milonas, D., Filippatos, T. D., Sourvinos, G., Papadogiannaki, M., Lydaki, E., Chamilos, G., & Kofteridis, D. P. (2023). Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates. Viruses. https://doi.org/10.3390/v15030756

Vancouver

Ioannou P, Katsigiannis A, Papakitsou I, Kopidakis I, Makraki E, Milonas D, et al. Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates. Viruses. 2023. doi:10.3390/v15030756

BibTeX
@article{Ioannou2023,
  author = {Ioannou, Petros and Katsigiannis, Athanasios and Papakitsou, Ioanna and Kopidakis, Ioannis and Makraki, Eirini and Milonas, Dimitris and Filippatos, Theodosios D and Sourvinos, George and Papadogiannaki, Marina and Lydaki, Evaggelia and Chamilos, Georgios and Kofteridis, Diamantis P},
  title = {Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15030756}
}
Kostenlos starten →